COMMUNIQUÉS West-GlobeNewswire

KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
04/06/2025
RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) -- As part of Saudi Arabia’s broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its [...]
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
04/06/2025
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE [...]
Aveanna Healthcare Holdings Completes Acquisition of Thrive Skilled Pediatric Care
04/06/2025
ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
04/06/2025
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
04/06/2025
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane [...]
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
04/06/2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, [...]
Cuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
04/06/2025
SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ CUPR ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
04/06/2025
Collaboration will leverage Rosy Wellness’ extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Daré expects to start recording [...]
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
04/06/2025
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well [...]
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
04/06/2025
Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA [...]
BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
04/06/2025
Underscores Hydrafacial’s leadership and value to providers and consumers LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently [...]
Elicio Therapeutics Secures $10 Million in Financing
04/06/2025
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or [...]
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
04/06/2025
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
04/06/2025
Phase 1 1 First-In-Human study designed to assess safety , tolerability , right dose for Phase 2 and early signs of efficacy of 177Lu-RAD20 2 in individuals with advanced HER2-positive solid tumors Previous clinical [...]
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
04/06/2025
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, [...]
FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT
04/06/2025
WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “ Company ”) today announced that it has executed an agreement to issue 1,650 of its Series A [...]
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
04/06/2025
HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based [...]
BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor
04/06/2025
Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig”), which acquired Streamex Exchange Corporation as its wholly owned subsidiary (“Streamex”) in May [...]
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
04/06/2025
June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical [...]

Pages